BioLineRx annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioLineRx R&D Spending Growth & History (BLRX)
BioLineRx's r&d spending was $8.1M for fiscal 2025.
View full BioLineRx company overviewBioLineRx annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.1M | −$1.1M | −11.54% |
| 2024 | 2024-12-31 | $9.1M | −$3.4M | −26.92% |
| 2023 | 2023-12-31 | $12.5M | −$5.1M | −28.99% |
| 2022 | 2022-12-31 | $17.6M | −$1.8M | −9.44% |
| 2021 | 2021-12-31 | $19.5M | $1.3M | +7.11% |
| 2020 | 2020-12-31 | $18.2M | −$5.3M | −22.46% |
| 2019 | 2019-12-31 | $23.4M | $3.6M | +18.33% |
| 2018 | 2018-12-31 | $19.8M | $298,000 | +1.53% |
| 2017 | 2017-12-31 | $19.5M | $8.3M | +74.55% |
| 2016 | 2016-12-31 | $11.2M | −$312,000 | −2.72% |
| 2015 | 2015-12-31 | $11.5M | — | — |
BioLineRx quarterly r&d spending
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.9M | $617,000 | +26.53% |
| Q1 2026 | 2026-03-31 | $2.5M | $905,000 | +55.76% |
| Q4 2025 | 2025-12-31 | $2.4M | — | — |
| Q3 2025 | 2025-09-30 | $1.7M | — | — |
| Q2 2025 | 2025-06-30 | $2.3M | $101,000 | +4.54% |
| Q1 2025 | 2025-03-31 | $1.6M | — | — |
| Q2 2024 | 2024-06-30 | $2.2M | −$781,000 | −25.98% |
| Q2 2023 | 2023-06-30 | $3.0M | −$2.4M | −44.28% |
| Q2 2022 | 2022-06-30 | $5.4M | $256,000 | +4.98% |
| Q2 2021 | 2021-06-30 | $5.1M | $499,000 | +10.75% |
| Q2 2020 | 2020-06-30 | $4.6M | −$662,000 | −12.49% |
| Q2 2019 | 2019-06-30 | $5.3M | $818,000 | +18.24% |
| Q2 2018 | 2018-06-30 | $4.5M | $422,000 | +10.39% |
| Q2 2017 | 2017-06-30 | $4.1M | — | — |
BioLineRx r&d spending trends
Over the last five fiscal years, BioLineRx's r&d spending decreased from $18.2M to $8.1M, a change of −$10.1M. The latest reported quarter, Q2 2026, shows $2.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioLineRx source filings ↗